Clinical Observations and Outcomes in Advanced Low-Grade Serous Carcinoma of the Ovary: Case Series from a Tertiary Cancer Center
- PMID: 38187842
- PMCID: PMC10767051
- DOI: 10.1007/s13193-023-01775-z
Clinical Observations and Outcomes in Advanced Low-Grade Serous Carcinoma of the Ovary: Case Series from a Tertiary Cancer Center
Abstract
Low-grade serous carcinoma (LGSC) is a rare histologic subtype of ovarian cancer. We present detailed management of 15 cases of advanced LGSC from a tertiary cancer center of India. Fifteen cases of advanced LGSC who underwent cytoreductive surgery (CRS) were analyzed from a prospectively maintained database. Baseline demographic characteristics, surgical details, and chemotherapy details were recorded. Descriptive statistics were summarized, and progression-free survival (PFS) and overall survival (OS) were estimated. The median age was 37 years. Nine patients had received NACT. All cases were FIGO stage III. Mean PCI was 15. Eleven patients had a completeness of cytoreduction score of 0-1. The median surgical time was 7.5 h; nine patients required multiple gastrointestinal resections. Median blood loss was 2500 ml. Median postoperative ventilation, ICU stay, and hospital stays were 1, 2, and 16 days, respectively. One patient had a grade III complication. Four patients received adjuvant chemotherapy. There was no postoperative mortality at the end of 90 days of surgery. All the patients except one were offered hormonal maintenance therapy. At a median follow-up of 43 months, 4 patients were disease-free, 9 had a recurrence, one died of disease progression, and one was lost to follow-up. Most recurrences were locoregional in the peritoneal cavity or pelvis. Four-year OS and PFS were 71.8% and 29.7%, respectively. Advanced LGSCs occur mostly in young premenopausal women with favorable oncologic outcomes. Optimal CRS is the mainstay of treatment. Relative chemo-resistance and hormone receptor positivity provide an excellent therapeutic opportunity for endocrine therapy.
Keywords: Cytoreductive surgery (CRS); Low-grade serous cancer (LGSC); Management; Overall survival (OS); Progression-free survival (PFS).
© Crown 2023.
Conflict of interest statement
Conflict of InterestThe authors declare no competing interests.
Figures
Similar articles
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
-
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3. Syst Rev. 2024. PMID: 39593159 Free PMC article.
-
Early high-dose cryoprecipitate to reduce mortality in adult patients with traumatic haemorrhage: the CRYOSTAT-2 RCT with cost-effectiveness analysis.Health Technol Assess. 2024 Nov;28(76):1-69. doi: 10.3310/JYTR6938. Health Technol Assess. 2024. PMID: 39545850 Free PMC article. Clinical Trial.
-
Tamoxifen for adults with hepatocellular carcinoma.Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014869. doi: 10.1002/14651858.CD014869.pub2. Cochrane Database Syst Rev. 2024. PMID: 39132750 Review.
-
Cryotherapy following total knee replacement.Cochrane Database Syst Rev. 2023 Sep 14;9(9):CD007911. doi: 10.1002/14651858.CD007911.pub3. Cochrane Database Syst Rev. 2023. PMID: 37706609 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Miscellaneous